Posted by Michael Wonder on 06 Dec 2022
Swissmedic approves Quviviq (daridorexant) – a first in class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning
5 December 2022 - Quviviq, Switzerland's first approved dual orexin receptor antagonist, offers a new targeted mechanism of action that decreases nighttime overactive wakefulness in insomnia.
Idorsia today announced that Swissmedic has granted marketing authorisation for Quviviq (daridorexant) for the treatment of adult patients with insomnia characterised by symptoms present for at least three months and considerable impact on daytime functioning.
